Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ('Intellia Therapeutics, Inc.') ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for future growth. Click for more on NTLA.

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...